Company intelligence / Profile preview

Protomer Technologies

Pasadena, California, United Statesprotomer.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Protomer Technologies has developed a proprietary MEPS platform for engineering next-generation responsive protein and peptide therapeutics. Their lead programs include pre-clinical candidates such as glucose-responsive insulin receptor agonists for diabetes. No published clinical results to date.

Therapeutic areas: Endocrinology
Modalities: Protein therapeuticsPeptide therapeuticsResponsive biotherapeutics
Industry: Biotech

Drug pipeline

1 asset

glucose-responsive insulin

Pre-clinical

Indications: Type 1 diabetes, Diabetes

Partnerships

JDRF T1D Fund investor/partner prior to acquisition

Beyond the preview

Go deeper on Protomer Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protomer Technologies.

Explore the full profile